Advise Saving Evenity for High-Risk Women With Osteoporosis

June 2019

Evenity (ee-VEN-ih-tee, romosozumab) is the first med to increase bone growth AND decrease bone breakdown for postmenopausal osteoporosis.

Other osteoporosis meds do one or the other. For example, Forteo (teriparatide) and Tymlos (abaloparatide) build bone. Bisphosphonates (alendronate, etc) and Prolia (denosumab) slow bone breakdown.

Evenity is the first "sclerostin inhibitor." It's an injectable monoclonal antibody that blocks this protein involved in bone metabolism.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote